4.7 Article

Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy

Journal

CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 70, Issue 6, Pages 1605-1617

Publisher

SPRINGER
DOI: 10.1007/s00262-020-02796-1

Keywords

Immunotherapy; Immune evasion; Methylation; Tumor immunogenicity

Funding

  1. National Research Foundation of Korea (NRF) - Korea government (MSIT) [NRF-2019R1C1C1004295]
  2. Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI17C0048]

Ask authors/readers for more resources

The study demonstrated a negative correlation between overall methylation aberrancy and tumor immunogenicity, indicating the importance of methylation aberrancy for tumors to evade immune surveillance. This highlights the need for further development of methylation biomarkers in cancer research.
Tumor immunogenicity is driven by various genomic and transcriptomic factors but the association with the overall status of methylation aberrancy is not well established. We analyzed The Cancer Genome Atlas pan-cancer database to investigate whether the overall methylation aberrancy links to the immune evasion of tumor. We created the definitions of hypermethylation burden, hypomethylation burden and methylation burden to establish the values that represent the degree of methylation aberrancy from human methylation 450 K array data. Both hypermethylation burden and hypomethylation burden significantly correlated with global methylation level as well as methylation subtypes defined in previous literatures. Then we evaluated whether methylation burden correlates with tumor immunogenicity and found that methylation burden showed a significant negative correlation with cytolytic activity score, which represent cytotoxic T cell activity, in pan-cancer (Spearman rho = - 0.37, p < 0.001) and 30 of 33 individual cancer types. Furthermore, this correlation was independent of mutation burden and chromosomal instability in multivariate regression analysis. We validated the findings in the external cohorts and outcomes of patients who were treated with immune checkpoint inhibitors, which showed that high methylation burden group had significantly poor progression-free survival (Hazard ratio 1.74, p = 0.038). Overall, the degree of methylation aberrancy negatively correlated with tumor immunogenicity. These findings emphasize the importance of methylation aberrancy for tumors to evade immune surveillance and warrant further development of methylation biomarker.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available